Article
Cell Biology
Chao Zheng, Dongdong Zhou, Weisong Li, Yanhui Duan, Minwen Xu, Jie Liu, Jingpei Cheng, Youban Xiao, Han Xiao, Tao Gan, Jianmin Liang, Dexian Zheng, Liefeng Wang, Shuyong Zhang
Summary: Pancreatic cancer (PC) is an aggressive malignancy with low survival rates and limited treatment options. The study investigated the antitumor activity of Oba01 ADC and its mechanism of targeting death receptor 5 (DR5) in PC models. The results showed that Oba01 demonstrated potent in vitro antitumor activity and induced cell death through various mechanisms including apoptosis and immune-mediated cytotoxicity. Combinational therapy with gemcitabine also enhanced the therapeutic effect of Oba01. These findings suggest that Oba01 can be a promising biotherapeutic approach for PC patients expressing DR5.
CELL DEATH & DISEASE
(2023)
Article
Oncology
Yezhe Cheng, Xiaoxi Yuan, Qiang Tian, Xiuying Huang, Yang Chen, Yuzhi Pu, Hu Long, Mingyu Xu, Yafei Ji, Jia Xie, Yuping Tan, Xi Zhao, Hongmei Song
Summary: The study aimed to enhance the intratumoral accumulation of an antibody-drug conjugate (ADC) and reduce its off-target toxicity. SKB264, a novel ADC targeting trophoblast antigen 2 (TROP2), showed promising pharmacologic profiles in vitro and in vivo, with stronger targeting effect and better antitumor activity compared to IMMU-132. These findings suggest the potential therapeutic efficacy of SKB264 for TROP2-positive tumors.
FRONTIERS IN ONCOLOGY
(2022)
Review
Engineering, Multidisciplinary
Ji-Min Dai, Xue-Qin Zhang, Jing-Yao Dai, Xiang-Min Yang, Zhi-Nan Chen
Summary: The modification of therapeutic antibodies is booming in research and development to improve efficacy. China, as an active player in the biopharmaceutical field, shows a great demand and potential in this area.
Article
Chemistry, Applied
Qian Wang, Hao Jiang, Hongli Zhang, Weiqiao Lu, Xiao Wang, Wenfeng Xu, Jia Li, Youjing Lv, Guoyun Li, Chao Cai, Guangli Yu
Summary: This study proposes a novel strategy of antibody-beta-glucan conjugates (AGC) to enhance the antitumor immune response to immune checkpoint blockade (ICB) therapy. AGC demonstrated powerful tumor suppression and promoted interaction between tumor cells and dendritic cells (DCs), thereby enhancing immunotherapeutic benefits.
CARBOHYDRATE POLYMERS
(2024)
Article
Cell Biology
Magdalena Rudzinska-Radecka, Lukasz Janczewski, Anna Gajda, Marlena Godlewska, Malgorzata Chmielewska-Krzesinska, Krzysztof Wasowicz, Piotr Podlasz
Summary: The study found that the phosphonate analog P-ITC can be used as a non-toxic treatment for zebrafish embryos and also shows anti-cancerogenic effects on various human tumor cell lines. Experimental results demonstrate that P-ITC significantly inhibits cancer cell growth, displaying versatile activity.
Article
Medicine, Research & Experimental
Josefa Dela Cruz Chuh, MaryAnn Go, Yvonne Chen, Jun Guo, Hanine Rafidi, Danielle Mandikian, Yonglian Sun, Zhonghua Lin, Kellen Schneider, Pamela Zhang, Rajesh Vij, Danielle Sharpnack, Pamela Chan, Cecile de la Cruz, Jack Sadowsky, Dhaya Seshasayee, James T. Koerber, Thomas H. Pillow, Gail D. Phillips, Rebecca K. Rowntree, C. Andrew Boswell, Katherine R. Kozak, Andrew G. Polson, Paul Polakis, Shang-Fan Yu, Peter S. Dragovich, Nicholas J. Agard
Summary: Early success with brentuximab vedotin in treating classical Hodgkin lymphoma led to the development of multiple MMAE antibody-drug conjugates, but most of these have not been successful in clinical trials. This study describes the development of second-generation therapeutic ADCs targeting Ly6E, with a focus on using DNA-damaging agents to improve durability of response. The new ADCs showed promising preclinical efficacy in driving tumor regression and reducing the likelihood of resistance compared to traditional MMAE-based conjugates.
Review
Biochemistry & Molecular Biology
Jenny Schunke, Volker Mailaender, Katharina Landfester, Michael Fichter
Summary: Finding a long-term cure for tumor patients remains challenging. Immunotherapies show promise by activating the immune system against tumors and modulating the tumor microenvironment. However, current methods often fail to sufficiently activate the immune system and have limitations such as drug degradation and non-specific uptake. Encapsulating immunomodulatory molecules into nanocarriers offers a solution by protecting cargo and targeting uptake by antigen-presenting cells. This approach allows for versatile immune system stimulation and improved anti-tumor responses with reduced toxicity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Long Qin, Long Wang, Junchang Zhang, Huinian Zhou, Zhiliang Yang, Yan Wang, Weiwen Cai, Fei Wen, Xiangyan Jiang, Tiansheng Zhang, Huili Ye, Bo Long, Junjie Qin, Wengui Shi, Xiaoying Guan, Zeyuan Yu, Jing Yang, Qi Wang, Zuoyi Jiao
Summary: This study identifies urokinase-type plasminogen activator receptor (uPAR) as a potential therapeutic target for diffuse-type gastric cancer (DGC), a subtype of gastric cancer with low HER2 positivity rate and insensitivity to chemotherapy and immune checkpoint inhibitors. The combination of anti-uPAR and anti-Programmed cell death protein 1 (PD-1) is shown to effectively inhibit tumor growth and prolong survival through multiple mechanisms. Furthermore, uPAR chimeric antigen receptor-expressing T cells demonstrate the ability to kill DGC cells and improve survival in preclinical models, especially when combined with PD-1 blockade therapy.
Article
Oncology
Maria Vitale, Filippo Scialo, Margherita Passariello, Eleonora Leggiero, Anna D'Agostino, Lorella Tripodi, Laura Gentile, Andrea Bianco, Giuseppe Castaldo, Vincenzo Cerullo, Claudia De Lorenzo, Lucio Pastore
Summary: Oncolytic virotherapy is an emerging cancer treatment approach that selectively infects and destroys cancer cells, enhancing the antitumoral immune response. This study demonstrates that the expression of immune checkpoint inhibitors can increase the efficacy of oncolytic virotherapy and may be a promising tool for cancer treatment.
FRONTIERS IN ONCOLOGY
(2022)
Article
Immunology
Arwa Ali, Menghan Gao, Alexandros Iskantar, Hai Wang, Alex Karlsson-Parra, Di Yu, Chuan Jin
Summary: This study evaluated the combination therapy of intratumoral administration of AlloDCs with systemic a4-1BB treatment and found that it significantly enhanced the anti-tumor effects in murine colon carcinoma and melanoma models. The combination treatment improved the tumor microenvironment, increased infiltration of activated immune cells, and led to a less immunosuppressive tumor microenvironment. These findings suggest the potential of this combination therapy for further investigation in clinical studies.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Gastroenterology & Hepatology
Haichuan Wang, Yi Zhou, Hongwei Xu, Xue Wang, Yi Zhang, Runze Shang, Marie O'Farrell, Stephanie Roessler, Carsten Sticht, Andreas Stahl, Matthias Evert, Diego F. Calvisi, Yong Zeng, Xin Chen
Summary: This study evaluated the therapeutic efficacy of the FASN inhibitor TVB3664 for HCC treatment and found that it has limited effectiveness as monotherapy, but can be combined with other drugs for improved results. These combination therapies can be developed based on driver oncogenes, supporting precision medicine approaches for HCC treatment.
Article
Oncology
Xing Yi Woo, Anuj Srivastava, Philip C. Mack, Joel H. Graber, Brian J. Sanderson, Michael W. Lloyd, Mandy Chen, Sergii Domanskyi, Regina Gandour-Edwards, Rebekah A. Tsai, James Keck, Mingshan Cheng, Margaret Bundy, Emily L. Jocoy, Jonathan W. Riess, William Holland, Stephen C. Grubb, James G. Peterson, Grace A. Stafford, Carolyn Paisie, Steven B. Neuhauser, R. Krishna Murthy Karuturi, Joshy George, Allen K. Simons, Margaret Chavaree, Clifford G. Tepper, Neal Goodwin, Susan D. Airhart, Primo N. Lara, Thomas H. Openshaw, Edison T. Liu, David R. Gandara, Carol J. Bult
Summary: Patient-derived xenograft models are important preclinical platforms for testing cancer therapeutics. This study describes a repository of genetically and clinically annotated lung cancer PDX models, which have been extensively characterized for histopathologic features, mutational profiles, gene expression, and copy-number aberrations. The genomic profiles of the PDX models are consistent with patient tumors, and these models serve as valuable platforms for translational cancer research.
Article
Oncology
Marjolein C. Stip, Mitchell Evers, Maaike Nederend, Chilam Chan, Karli R. Reiding, Mirjam J. Damen, Albert J. R. Heck, Sofia Koustoulidou, Ruud Ramakers, Gerard C. Krijger, Remmert de Roos, Edouard Souteyrand, Annelisa M. Cornel, Miranda P. Dierselhuis, Marco Jansen, Mark de Boer, Thomas Valerius, Geert van Tetering, Jeanette H. W. Leusen, Friederike Meyer-Wentrup
Summary: Researchers engineered an antibody called IgA3.0 ch14.18, which shows promise as a new therapy for neuroblastoma. The antibody has a longer half-life, increased protein stability, and potent tumor-killing abilities.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Polymer Science
Airi Harui, Michael D. Roth
Summary: In this study, peri-tumor administration of hydrogel-encapsulated anti-CTLA-4 was found to specifically target tumor-draining lymph nodes, and the inclusion of hyaluronidase enhanced this targeting effect. These findings provide a theoretical basis for further optimizing immunotherapy.
Article
Oncology
Lingling Ou, Huaishan Wang, Hui Huang, Zhiyan Zhou, Qiang Lin, Yeye Guo, Tara Mitchell, Alexander C. Huang, Giorgos Karakousis, Lynn Schuchter, Ravi Amaravadi, Wei Guo, Joseph Salvino, Meenhard Herlyn, Xiaowei Xu
Summary: This study reveals the exhausted immunophenotypes and limited anti-tumor capacity of tumor-infiltrating gamma delta T cells in melanoma 3D models. Checkpoint inhibitors and epigenetic modifiers enhance the anti-tumor functions of gamma delta T cells. These findings have important implications for immunotherapy.
CLINICAL AND TRANSLATIONAL MEDICINE
(2022)
